Novel cyclopeptides for the design of MMP directed delivery devices: A novel smart delivery paradigm

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1713-1721

  Moustoifa, El Farouck ^a   Alouini, Mohamed Anis ^a,b,c   Salaün, Arnaud ^a   Berthelot, Thomas ^b   Bartegi, Aghleb ^c   Albenque Rubio, Sandra ^a   Déléris, Gérard ^a  

^a CENTRE D ETUDES NUCLÉAIRES DE BORDEAUX GRADIGNAN   (France)

^b CNRS UMR 3299   (France)

^c Unite de Recherche 02/UR/09 01 Biochimie des Proteines et Interactions Moleculaires   (Tunisia)

Author keywords

cancer; cyclic peptide; delivery device; fluorescent substrate; MMP

Indexed keywords

AMINO ACID; CYCLO[GLYCYLPROLYLGLUTAMYLGLYCYLLEUCYLLEUCYLGLYCYLALANYLLYSYL(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)GLYCYLPROLYLGLUTAMYLGLYCYLLEUCYLLEUCYLGLYCYLALANYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)GLUTAMIC ACID]; CYCLO[GLYCYLPROLYLGLYCYLGLYCYLVALYLVALYLGLYCYLPROLYLLYSY(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)GLYCYLPROLYLGLYCYLGLYCYLVALYLVALYLGLYCYLPROLYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)GLUTAMIC ACID]; CYCLO[PROLYLPROLYLGLYCYLALANYLTYROSYLHISTIDYLGLYCYLALANYLLYSYL(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)PROLYLPROLYLGLYCYLALANYLTYROSYLHISTIDYLGLYCYLALANYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)GLUTAMIC ACID]; CYCLOPEPTIDE; LYSYL(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)GLYCYLPROLYLGLUTAMINYLGLYCYLLEUCYLLEUCYLGLYCYLALANYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)ALANINE CARBOXYL AMINE; LYSYL(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)GLYCYLPROLYLGLYCYLGLYCYLVALYLVALYLGLYCYLPROLYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)ALANINE CARBOXYL AMINE; LYSYL(7 DIETHYLAMINO COUMARIN 3 CARBOXYLIC ACID)PROLYLPROLYLGLYCYLALANYLTYROSYLHISTIDYLGLYCYLALANYLLYSYL(7 METHOXY COUMARIN 3 CARBOXYLIC ACID)ALANINE CARBOXYL AMINE; MATRIX METALLOPROTEINASE; RESIN; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE INHIBITOR; PEPTIDE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYCLIZATION; DRUG DELIVERY SYSTEM; ENZYME ASSAY; ENZYME KINETICS; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; AMINO ACID SEQUENCE; DRUG DESIGN; KINETICS; MOLECULAR GENETICS; SYNTHESIS;

AMINO ACID SEQUENCE; CYCLIZATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; KINETICS; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; PEPTIDES; MATRIX METALLOPROTEINASE INHIBITORS;

EID: 77955471054     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0164-0     Document Type: Article

References (37)

1. LA Liotta 1980 Metastatic potential correlates with enzymatic degradation of basement membrane collagen Nature 284 67 8 10.1038/284067a0 6243750
2. WG Stetler-Stevenson 1994 Progelatinase A activation during tumor cell invasion Invasion Metastasis 14 259 68 7657518
3. H Nagaseand JF Woessner 1999 Matrix metalloproteinases J Biol Chem. 274 21491 4 10.1074/jbc.274.31.21491 (Pubitemid 29359963)
4. AK Lucio-Eterovic Y Piao JF de Groot 2009 Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clin Cancer Res. 15 4589 99 10.1158/1078-0432.CCR-09-0575 19567589
5. R Roy G Louis KR Loughlin D Wiederschain SM Kilroy CC Lamb, et al. 2008 Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species Clin Cancer Res. 14 6610 7 10.1158/1078-0432.CCR-08-1136 18927302
6. PC Brooks S Stromblad LC Sanders TL von Schalscha RT Aimes WG Stetler-Stevenson, et al. 1996 Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 Cell 85 683 93 10.1016/S0092-8674(00)81235-0 8646777 (Pubitemid 26181048)
7. S Zucker J Cao WT Chen 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 6642 50 10.1038/sj.onc.1204097 11426650 (Pubitemid 32197703)
8. LM Coussens B Fingleton LM Matrisian 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science (New York, NY) 295 2387 92
9. CM Overall 2002 Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites Mol Biotechnol. 22 51 86 10.1385/MB:22:1:051 12353914
10. B Fingleton 2003 Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects Expert Opin Ther Targets. 7 385 97 10.1517/14728222.7.3.385 12783574 (Pubitemid 36722223)
11. LJ McCawley LM Matrisian 2001 Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 13 534 40 10.1016/S0955-0674(00)00248- 9 11544020 (Pubitemid 32817010)
12. T Aoki T Sumii T Mori X Wang EH Lo 2002 Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats Stroke 33 2711 7 10.1161/01.STR.0000033932.34467.97 12411666 (Pubitemid 35266446)
13. CM Overall 2004 Dilating the degradome: matrix metalloproteinase-2 cuts to the heart of the matter Biochem J. 383 E5 7 10.1042/BJ20041433 15508185
14. WC Parks CL Wilson YS Lopez-Boado 2004 Matrix metalloproteinases as modulators of inflammation and innate immunity Nature Rev Immunol. 4 617 29 10.1038/nri1418
15. AJ Minn 2005 Genes that mediate breast cancer metastasis to lung Nature 436 518 24 10.1038/nature03799 16049480 (Pubitemid 41112921)
16. AJ Minn Y Kang I Serganova GP Gupta DD Giri M Doubrovin, et al. 2005 Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors J Clin Invest. 115 44 55 15630443
17. DC Radisky DD Levy LE Littlepage H Liu CM Nelson JE Fata, et al. 2005 Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability Nature 436 123 7 10.1038/nature03688 16001073 (Pubitemid 40966197)
18. B Weigelt JL Peterse LJ van 't Veer 2005 Breast cancer metastasis: markers and models Nat Rev Cancer 5 591 602 10.1038/nrc1670 16056258 (Pubitemid 41081385)
19. JL Lauer-Fields T Broder T Sritharan L Chung H Nagase GB Fields 2001 Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates Biochemistry 40 5795 803 10.1021/bi0101190 11341845 (Pubitemid 32440884)
20. DG Vartak RA Gemeinhart 2007 Matrix metalloproteases: underutilized targets for drug delivery J Drug Target. 15 1 20 10.1080/10611860600968967 17365270 (Pubitemid 47161328)
21. Y Chau FE Tan R Langer 2004 Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX Bioconjug Chem. 15 931 41 10.1021/bc0499174 15264885 (Pubitemid 38981971)
22. JR Tauro BS Lee SS Lateef RA Gemeinhart 2008 Matrix metalloprotease selective peptide substrates cleavage within hydrogel matrices for cancer chemotherapy activation Peptides 29 1965 73 10.1016/j.peptides.2008.06.021 18652863
23. JR Tauro RA Gemeinhart 2005 Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrices Bioconjug Chem. 16 1133 9 10.1021/bc0501303 16173790 (Pubitemid 41368115)
24. JR Tauro RA Gemeinhart 2005 Extracellular protease activation of chemotherapeutics from hydrogel matrices: a new paradigm for local chemotherapy Mol Pharm. 2 435 8 10.1021/mp050028n 16196497 (Pubitemid 41503685)
25. GI Murray ME Duncan P O'Neil WT Melvin JE Fothergill 1996 Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer Nature Med. 2 461 2 10.1038/nm0496–461 8597958
26. CM Overall O Kleifeld 2006 Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat Rev Cancer 6 227 39 10.1038/nrc1821 16498445 (Pubitemid 43292566)
27. AR Folgueras AM Pendas LM Sanchez C Lopez-Otin 2004 Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies Int J Dev Biol. 48 411 24 10.1387/ijdb.041811af 15349816 (Pubitemid 39360392)
28. T Berthelot G Lain L Latxague G Deleris 2004 Synthesis of novel fluorogenic L-Fmoc lysine derivatives as potential tools for imaging cells J Fluoresc. 14 671 5 10.1023/B:JOFL.0000047216.37306.79 15649018
29. T Berthelot JC Talbot G Lain G Deleris L Latxague 2005 Synthesis of N epsilon-(7-diethylaminocoumarin-3-carboxyl)- and N epsilon-(7-methoxycoumarin-3- carboxyl)-L-Fmoc lysine as tools for protease cleavage detection by fluorescence J Pept Sci. 11 153 60 10.1002/psc.608 15635646 (Pubitemid 40347547)
30. H Nagase BF Gregg 1996 Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides Pept Sci. 40 399 416
31. GB Fields 1991 A model for interstitial collagen catabolism by mammalian collagenases J Theor Biol. 153 585 602 10.1016/S0022-5193(05)80157-2 1666905
32. J Ochieng R Fridman P Nangia-Makker DE Kleiner LA Liotta WG Stetler-Stevenson, et al. 2002 Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and-9 Biochemistry 33 14109 14 10.1021/bi00251a020
33. C Niyibizi R Chan JJ Wu D Eyre 1994 A 92 kDa gelatinase (MMP-9) cleavage site in native type V collagen Biochem Biophys Res Commun. 202 328 33 10.1006/bbrc.1994.1931 8037728
34. C Flouzat F Marguerite F Croizet M Percebois A Monteil M Combourieu 1997 Solid-phase synthesis of "head-to-side chain" cyclic tripeptides using allyl deprotection Tetrahedron Lett. 38 1191 4 10.1016/S0040-4039(97)00061-0 (Pubitemid 27076180)
35. M Planas E Bardají G Barany 2000 Synthesis of cyclic peptide hybrids with amino acid and nucleobase side-chains Tetrahedron Lett. 41 4097 100 10.1016/S0040-4039(00)00550-5
36. A Napolitano I Bruno P Rovero R Lucas MP Peris L Gomez-Paloma, et al. 2001 Synthesis, structural aspects and bioactivity of the marine cyclopeptide hymenamide C Tetrahedron 57 6249 55 10.1016/S0040-4020(01)00579-8 (Pubitemid 32709695)
37. B Gogly N Groult W Hornebeck G Godeau B Pellat 1998 Collagen Zymography as a Sensitive and Specific Technique for the Determination of Subpicogram Levels of Interstitial Collagenase Anal Biochem. 255 211 6 10.1006/abio.1997. 2318 9451506 (Pubitemid 28082084)